Regulation of p53 functions: Let's meet at the nuclear bodies

Current Opinion in Cell Biology

Volumn 15, Issue 3, 2003, Pages 351-357

  Gostissa, Monica ^a   Hofmann, Thomas G ^b   Will, Hans ^b   Del Sal, Giannino ^a,c  

^a Lab Naz Consorzio I   (Italy)

^b LEIBNIZ INSTITUTE FOR EXPERIMENTAL VIROLOGY   (Germany)

^c UNIVERSITY OF TRIESTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53;

APOPTOSIS; CANCER INHIBITION; CELL CYCLE; CELL NUCLEUS INCLUSION BODY; CELLULAR DISTRIBUTION; DOWNSTREAM PROCESSING; GENE CONTROL; GENOME; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN INTERACTION; REVIEW; TRANSLATION REGULATION;

EID: 0038022702     PISSN: 09550674     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0955-0674(03)00038-3     Document Type: Review

References (54)

1. Vogelstein B., Lane D., Levine A.J. Surfing the p53 network. Nature. 408:2000;307-310.
2. Vousden K.H., Lu X. Live or let die: the cell's response to p53. Nat. Rev. Cancer. 2:2002;594-604.
3. Flores E.R., Tsai K.Y., Crowley D., Sengupta S., Yang A., McKeon F., Jacks T. p63 and p73 are required for p53-dependent apoptosis in response to DNA damage. Nature. 416:2002;560-564 Using cells derived from mice deficient for one or a combination of p53 family members, the author demonstrate that the combined loss of p63 and p73 results in the failure of cells containing functional p53 to undergo apoptosis in response to DNA damage.
4. Ryan K.M., Phillips A.C., Vousden K.H. Regulation and function of the p53 tumour suppressor protein. Curr. Opin. Cell Biol. 13:2001;332-337.
5. Momand J., Wu H.H., Dasgupta G. MDM2-master regulator of the p53 tumour suppressor protein. Gene. 242:2000;15-29.
6. •].
7. •].
8. •]) establish that phosphorylation of p53 mediates recruitment of the prolyl isomerase Pin1, which promotes a conformational change in the protein. This event is required for full activation of the p53 response.
9. Meek D.W. Mechanisms of switching on p53: a role for covalent modification? Oncogene. 18:1999;7666-7675.
10. Ayed A., Mulder F.A., Yi G.S., Lu Y., Kay L.E., Arrowsmith C.H. Latent and active p53 are identical in conformation. Nat. Struct. Biol. 8:2001;756-760.
11. McKinney K., Prives C. Efficient specific DNA binding by p53 requires both its central and C-terminal domains as revealed by studies with high-mobility group 1 protein. Mol. Cell Biol. 22:2002;6797-6808 In this study, the authors analyse the ability of p53 to bind to bended and supercoiled DNA and provide a demonstration that, under these conditions, the carboxyl terminus of p53 is important for promoting DNA binding. Both the sequence-specific DNA-binding domain and the carboxyl terminus therefore cooperates to recognise sequence and structure in genomic DNA.
12. Espinosa J.M., Emerson B.M. Transcriptional regulation by p53 through intrinsic DNA/chromatin binding and site-directed cofactor recruitment. Mol. Cell. 8:2001;57-69.
13. Kaeser M.D., Iggo R.D. Chromatin immunoprecipitation analysis fails to support the latency model for regulation of p53 DNA binding activity in vivo. Proc. Natl. Acad. Sci. U.S.A. 99:2002;95-100 Using the chromatin immunoprecipitation (ChiP) approach, the authors provide clear evidence that, in vivo, p53 is bound to its target promoters with the same affinity in the absence or in the presence of DNA damage. This suggests that activation of p53-mediated transcription does not require increased DNA binding.
14. Ito A., Kawaguchi Y., Lai C.H., Kovacs J.J., Higashimoto Y., Appella E., Yao T.P. MDM2-HDAC1-mediated deacetylation of p53 is required for its degradation. EMBO J. 21:2002;6236-6245.
15. Jimenez G.S., Khan S.H., Stommel J.M., Wahl G.M. p53 regulation by post-translational modification and nuclear retention in response to diverse stresses. Oncogene. 18:1999;7656-7665.
16. Giannakakou P., Sackett D., Ward Y., Webster K.R., Blagosklonny M.V., Fojo T. p53 is associated with microtubules and uses dynein-dependent transport for nuclear accumulation. Nat. Cell Biol. 2:2000;709-717.
17. Boisvert F.M., Kruhlak M.J., Box A.K., Hendzel M.J., Bazett-Jones D.P. The transcription coactivator CBP is a dynamic component of the promyelocytic leukemia nuclear body. J. Cell Biol. 152:2001;1099-1106.
18. Muratani M., Gerlich D., Janicki S.M., Gebhard M., Eils R., Spector D.L. Metabolic-energy-dependent movement of PML bodies within the mammalian cell nucleus. Nat. Cell Biol. 4:2002;106-110 Using expression of a yellow fluorescent protein tagged Sp100 protein as an integral promyelocytic leukaemia nuclear body (PML NB) component, the authors show that, based on their dynamic properties in living cells, three different classes of PML NBs can be distinguished. These results suggest that functionally different PML NB classes exist within a cell.
19. Everett R.D. DNA viruses and viral proteins that interact with PML nuclear bodies. Oncogene. 20:2001;7266-7273.
20. Jensen K., Shiels C., Freemont P.S. PML protein isoforms and the RBCC/TRIM motif. Oncogene. 20:2001;7223-7233.
21. Borden K.L. Pondering the promyelocytic leukemia protein (PML) puzzle: possible functions for PML nuclear bodies. Mol. Cell Biol. 22:2002;5259-5269.
22. Wang Z.G., Ruggero D., Ronchetti S., Zhong S., Gaboli M., Rivi R., Pandolfi P.P. PML is essential for multiple apoptotic pathways. Nat. Genet. 20:1998;266-271.
23. Zhong S., Muller S., Ronchetti S., Freemont P.S., Dejean A., Pandolfi P.P. Role of SUMO-1-modified PML in nuclear body formation. Blood. 95:2000;2748-2753.
24. Ishov A.M., Sotnikov A.G., Negorev D., Vladimirova O.V., Neff N., Kamitani T., Yeh E.T., Strauss J.F. 3rd, Maul G.G. PML is critical for ND10 formation and recruits the PML-interacting protein daxx to this nuclear structure when modified by SUMO-1. J. Cell Biol. 147:1999;221-234.
25. Zhong S., Salomoni P., Pandolfi P.P. The transcriptional role of PML and the nuclear body. Nat. Cell Biol. 2:2000;E85-E90.
26. Salomoni P., Pandolfi P.P. The role of PML in tumour suppression. Cell. 108:2002;165-170.
27. Kentsis A., Gordon R.E., Borden K.L. Self-assembly properties of a model RING domain. Proc. Natl. Acad. Sci. U.S.A. 99:2002;667-672.
28. Best J.L., Ganiatsas S., Agarwal S., Changou A., Salomoni P., Shirihai O., Meluh P.B., Pandolfi P.P., Zon L.I. SUMO-1 protease-1 regulates gene transcription through PML. Mol. Cell. 10:2002;843-855 The authors identified SuPr-1, a SUMO-1-specific protease, as an activator for c-Jun-dependent transcription that is independent of c-Jun phosphorylation. They provide evidence that SuPr-1 acts on transcriptional activation in part in a promyelocytic leukaemia protein (PML)-dependent manner by altering the subcellular distribution of the transcriptional regulators PML, CBP and Daxx. This paper indicates an important transcriptional regulatory function of SUMO proteases.
29. Yang S., Kuo C., Bisi J.E., Kim M.K. PML-dependent apoptosis after DNA damage is regulated by the checkpoint kinase hCds1/Chk2. Nat. Cell Biol. 4:2002;865-870 This paper demonstrates a link between the DNA damage checkpoint kinase hCds1/Chk2 and promyelocytic leukaemia protein (PML) through an ATM-hCds1→Chk2→PML pathway. The authors show that Chk2 interacts with PML IV and phosphorylates it at Ser117, triggering an unknown PML-dependent apoptosis pathway in the absence of p53.
30. Perlman R., Schiemann W.P., Brooks M.W., Lodish H.F., Weinberg R.A. TGF-beta-induced apoptosis is mediated by the adapter protein Daxx that facilitates JNK activation. Nat. Cell Biol. 3:2001;708-714.
31. Wasylyk C., Schlumberger S.E., Criqui-Filipe P., Wasylyk B. Sp100 interacts with ETS-1 and stimulates its transcriptional activity. Mol. Cell Biol. 22:2002;2687-2702.
32. Wu W.S., Vallian S., Seto E., Yang W.M., Edmondson D., Roth S., Chang K.S. The growth suppressor PML represses transcription by functionally and physically interacting with histone deacetylases. Mol. Cell Biol. 21:2001;2259-2268.
33. Khan M.M., Nomura T., Kim H., Kaul S.C., Wadhwa R., Shinagawa T., Ichikawa-Iwata E., Zhong S., Pandolfi P.P., Ishii S. Role of PML and PML-RARalpha in Mad-mediated transcriptional repression. Mol. Cell. 7:2001;1233-1243.
34. Fogal V., Gostissa M., Sandy P., Zacchi P., Sternsdorf T., Jensen K., Pandolfi P.P., Will H., Schneider C., Del Sal G. Regulation of p53 activity in nuclear bodies by a specific PML isoform. EMBO J. 19:2000;6185-6195.
35. Ferbeyre G., de Stanchina E., Querido E., Baptiste N., Prives C., Lowe S.W. PML is induced by oncogenic ras and promoters premature senescence. Genes Dev. 14:2000;2015-2027.
36. Pearson M., Carbone R., Sebastiani C., Cioce M., Fagioli M., Saito S., Higashimoto Y., Appella E., Minucci S., Pandolfi P.P.et al. PML regulates p53 acetylation and premature senescence induced by oncogenic Ras. Nature. 406:2000;207-210.
37. Guo A., Salomoni P., Luo J., Shih A., Zhong S., Gu W., Pandolfi P.P. The function of PML in p53-dependent apoptosis. Nat. Cell Biol. 2:2000;730-736.
38. Carbone R., Pearson M., Minucci S., Pelicci P.G. PML NBs associate with the hMre11 complex and p53 at sites of irradiation induced DNA damage. Oncogene. 21:2002;1633-1640.
39. Bischof O., Kirsh O., Pearson M., Itahana K., Pelicci P.G., Dejean A. Deconstructing PML-induced premature senescence. EMBO J. 21:2002;3358-3369 This paper is one of the few studies dedicated to analyse the behaviour of different promyelocytic leukaemia protein (PML) isoforms. The authors demonstrate that, in human normal fibroblasts, only PML IV is able to induce premature senescence and to activate p53. This effect, while mediated by interaction between PML, CBP and p53, seems not to require the integrity of nuclear bodies.
40. Negorev D., Maul G.G. Cellular proteins localized at and interacting within ND10/PML nuclear bodies/PODs suggest functions of a nuclear depot. Oncogene. 20:2000;7234-7242.
41. Hofmann T.G., Moller A., Sirma H., Zentgraf H., Taya Y., Droge W., Will H., Schmitz M.L. Regulation of p53 activity by its interaction with homeodomain-interacting protein kinase-2. Nat. Cell Biol. 4:2002;1-10.
42. D'Orazi G., Cecchinelli B., Bruno T., Manni I., Higashimoto Y., Saito S., Gostissa M., Coen S., Marchetti A., Del Sal G.et al. Homeodomain-interacting protein kinase-2 phosphorylates p53 at Ser 46 and mediates apoptosis. Nat. Cell Biol. 4:2002;11-19.
43. Oda K., Arakawa H., Tanaka T., Matsuda K., Tanikawa C., Mori T., Nishimori H., Tamai K., Tokino T., Nakamura Y.et al. p53AIP1, a potential mediator of p53-dependent apoptosis, and its regulation by Ser-46-phosphorylated p53. Cell. 102:2000;849-862.
44. Luo J., Nikolaev A.Y., Imai S., Chen D., Su F., Shiloh A., Guarente L., Gu W. Negative control of p53 by Sir2alpha promotes cell survival under stress. Cell. 107:2001;137-148.
45. Vaziri H., Dessain S.K., Ng Eaton E., Imai S.I., Frye R.A., Pandita T.K., Guarente L., Weinberg R.A. hSIR2(SIRT1) functions as an NAD-dependent p53 deacetylase. Cell. 107:2001;149-159.
46. Langley E., Pearson M., Faretta M., Bauer U.M., Frye R.A., Minucci S., Pelicci P.G., Kouzarides T. Human SIR2 deacetylates p53 and antagonizes PML/p53-induced cellular senescence. EMBO J. 21:2002;2383-2396 This paper is the first report of a deacetylase that is localized to promyelocytic leukaemia protein (PML) nuclear bodies. SIRT1 is recruited to nuclear bodies by binding to PML, deacetylates p53 and counteracts PML-mediated p53 activation.
47. Everett R.D., Meredith M., Orr A., Cross A., Kathoria M., Parkinson J. A novel ubiquitin-specific protease is dynamically associated with the PML nuclear domain and binds to a herpesvirus regulatory protein. EMBO J. 16:1997;1519-1530.
48. Li M., Chen D., Shiloh A., Luo J., Nikolaev A.Y., Qin J., Gu W. Deubiquitination of p53 by HAUSP is an important pathway for p53 stabilization. Nature. 416:2002;648-653 In this paper, the authors demonstrate that a specific enzyme is responsible for de-ubiquitinating p53, resulting in its stabilisation and induction of apoptosis. Therefore, ubiquitination may represent another tunable step for controlling protein activity.
49. Bischof O., Kim S.H., Irving J., Beresten S., Ellis N.A., Campisi J. Regulation and localization of the Bloom syndrome protein in response to DNA damage. J. Cell Biol. 153:2001;367-380.
50. Lombard D.B., Guarente L. Nijmegen breakage syndrome disease protein and MRE11 at PML nuclear bodies and meiotic telomeres. Cancer Res. 60:2000;2331-2334.
51. D'Amours D., Jackson S.P. The Mre11 complex: at the crossroads of DNA repair and checkpoint signalling. Nat. Rev. Mol. Cell Biol. 3:2002;317-327.
52. Yang Q., Zhang R., Wang X.W., Spillare E.A., Linke S.P., Subramanian D., Griffith J.D., Li J.L., Hickson I.D., Shen J.C.et al. The processing of Holliday junctions by BLM and WRN helicases is regulated by p53. J. Biol. Chem. 277:2002;31980-31987.
53. MacLachlan T.K., Takimoto R., El-Deiry W.S. BRCA1 directs a selective p53-dependent transcriptional response towards growth arrest and DNA repair targets. Mol. Cell Biol. 22:2002;4280-4292.
54. Zink D., Mayr C., Janz C., Wiesmuller L. Association of p53 and MSH2 with recombinative repair complexes during S phase. Oncogene. 21:2002;4788-4800.